术中使用小剂量右美托咪定对乳腺癌手术患者预后的影响

杨笑萱, 朱珊, 钱程, 储晓英

Effect of intraoperative use of low-dose dexmedetomidine on the prognosis of patients undergoing breast cancer surgery

YANG Xiaoxuan, ZHU Shan, QIAN Cheng, CHU Xiaoying

表3 乳腺癌患者术后生存风险影响因素分析

Tab 3 Influencing factors of postoperative survival risk in patients with breast cancer

Influencing factor Univariate analysis Multivariate analysis HR(95%CI) P value HR(95%CI) P value Age 1.02 (1.00, 1.03) 0.032 1.01 (0.99, 1.04) 0.062 BMI 1.01 (0.98, 1.03) 0.891 1.00 (0.99, 1.01) 0.603 Chemotherapy 0.98 (0.95, 1.00) 0.063 0.98 (0.95, 1.11) 0.062 Radiotherapy 0.54 (0.24, 1.47) 0.041 0.55 (0.26, 1.54) 0.033 Hormonal therapy 1.10 (0.56, 1.48) 0.732 0.93 (0.65, 1.33) 0.562 ER+ 0.98 (0.45, 1.54) 0.087 1.12 (0.66, 1.69) 0.118 PR+ 1.09 (0.53, 1.44) 0.228 1.22 (0.64, 1.73) 0.215 HER2+ 1.02 (0.51, 1.49) 0.198 1.12 (0.58, 1.63) 0.115 Ki67 1.15 (1.01, 1.22) 0.021 1.13 (1.09, 1.18) 0.033 ASA classification 0.97 (0.95, 1.01) 0.067 1.01 (0.97, 1.04) 0.632 TMN stage 0.029 0.032 0 0.99 (0.95, 1.05) 1.25 (0.74, 2.09) Ⅰ 1.15 (0.64, 1.71) 1.24 (0.46, 2.12) ⅡA 1.09 (0.52, 1.51) 0.96 (0.62, 1.38) ⅡB 1.16 (0.88, 1.23) 1.21 (1.01, 1.58) Ⅲ 1.23 (0.74, 1.74) 1.26 (0.87, 1.84) Type of surgery 0.781 0.593 Breast-conserving surgery 1.09 (0.84, 1.52) 1.08 (0.73, 1.59) Mastectomy 0.98 (0.91, 1.15) 1.02 (0.79, 1.69) Duration of anesthesia 1.02 (0.85, 1.36) 0.232 0.99 (0.69, 1.23) 0.312 Remifentanil 0.69 (0.34, 1.89) 0.538 0.74 (0.49, 1.09) 0.381 Sufentanyl 0.87 (0.39, 1.41) 0.667 0.98 (0.71, 1.29) 0.769 Propofol 1.01 (0.88, 1.29) 0.517 1.10 (0.89, 1.31) 0.487 Cisatracurium 1.05 (0.91, 1.25) 0.473 1.08 (0.88, 1.27) 0.388 Inhalable anesthetic 0.94 (0.73, 1.27) 0.081 0.92 (0.87, 1.08) 0.057 VAS score when leaving PACU 1.02 (0.81, 1.19) 0.790 1.10 (0.81, 1.19) 0.682 Dexmedetomidine 1.15 (0.62, 2.16) 0.626 1.17 (0.62, 2.20) 0.673